According to BioMarin Pharmaceutical's latest financial reports the company's current EPS (TTM) is โน66.77. In 2022 the company made an earnings per share (EPS) of โน65.91 an increase over its 2021 EPS that were of -โน30.01.
Year | EPS | Change |
---|---|---|
2023 (TTM) | โน64.15 | -2.68% |
2022 | โน65.91 | -319.62% |
2021 | -โน30.01 | -107.38% |
2020 | โน406.47 | -3485.71% |
2019 | -โน12.01 | -67.44% |
2018 | -โน36.87 | -34.85% |
2017 | -โน56.60 | -83.21% |
2016 | -โน337.01 | 263.89% |
2015 | -โน92.61 | 18.68% |
2014 | -โน78.04 | -28.91% |
2013 | -โน109.76 | 34.74% |
2012 | -โน81.47 | 93.88% |
2011 | -โน42.02 | -124.5% |
2010 | โน171.51 | |
2009 | N/A | -100% |
2008 | โน27.44 | -300% |
2007 | -โน13.72 | -54.29% |
2006 | -โน30.01 | -67.89% |
2005 | -โน93.47 | -62.54% |
2004 | -โน249.54 | 136.59% |
2003 | -โน105.48 | -15.17% |
2002 | -โน124.34 | -11.59% |
2001 | -โน140.63 | 56.19% |
2000 | -โน90.04 | 10.53% |
1999 | -โน81.47 |